Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Aura Biosciences, Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that the U.S. Food... | June 30, 2022
United Kingdom Aura Biosciences Inc Drug Administration Exchange Commission Head Of Regulatory Affairs Aura Division Of Oncology
Source: marketscreener.com